Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.131NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.274NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.25NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.235NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.65NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.45NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.50NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.60NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.52NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
W.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.250NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.63NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.27NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.23NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.130NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.44NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.469NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.62NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.80 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.43.8 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.128 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.21NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.220NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.58NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.258.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.438NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.257NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.5.4 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.323NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.15NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.105 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.4.4 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.4.9 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.398NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.94 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.18NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.18NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XWNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.1.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KG.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XDJNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.3.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GK.1.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.5.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.36.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.86.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LV.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.23NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GE.1.2.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used